医療実践で行動する.

Same author

Breast cancer germline multigene panel testing in mainstream oncology based on clinical-public health utility: ESMO Precision Oncology Working Group recommendations.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Corrigendum to "Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group": [Ann Oncol 35 (2024) 588-606].

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab.

NPJ breast cancer·2024

Same author

Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Same author

Programmed intermittent epidural bolus regimen vs continuous epidural infusion: a retrospective study of motor block and obstetric outcomes using the Robson's Ten Group Classification System.

International journal of obstetric anesthesia·2024

Same author

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

関連する実験動画

医療実践で行動する.

関連する概念動画

Breast cancer germline multigene panel testing in mainstream oncology based on clinical-public health utility: ESMO Precision Oncology Working Group recommendations.

Corrigendum to "Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group": [Ann Oncol 35 (2024) 588-606].

Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab.

Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.

Programmed intermittent epidural bolus regimen vs continuous epidural infusion: a retrospective study of motor block and obstetric outcomes using the Robson's Ten Group Classification System.

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

関連する実験動画

医療実践で行動する.

関連する概念動画

関連記事

Breast cancer germline multigene panel testing in mainstream oncology based on clinical-public health utility: ESMO Precision Oncology Working Group recommendations.

Corrigendum to "Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group": [Ann Oncol 35 (2024) 588-606].

Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab.

Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.

Programmed intermittent epidural bolus regimen vs continuous epidural infusion: a retrospective study of motor block and obstetric outcomes using the Robson's Ten Group Classification System.

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.